Phase 1b Study to Investigate ABBV-CLS-7262's Safety, Tolerability & Pharmacokinetics in Vanishing White Matter Patients
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
ABBV-CLS-7262 is an investigational drug being researched for the treatment of Vanishing
White Matter disease. This is a 96-week, open-label, single arm study.
Subjects will attend regular visits during the course of the study and complete medical
assessments, blood tests, checking for side effects, and completing questionnaires.